Biomedical and Life Sciences
Research Degrees MPhil/PhD
MSc in Biomedical Science (by Research)
Doctor of Medicine (MD)
Taught Courses MSc in Biomedicine
MSc in Medical Biotechnology and Leadership
Number of Postgraduate Students 40
Head of Department Dr Jane Owen-Lynch
Postgraduate Enquiries tel: +44 (0)1524 593936
e-mail:
shm-pg-admissions@lancaster.ac.uk
Website
www.lancs.ac.uk/shm/bls/
Location Biological Sciences Building
Professor David Allsop Biomedical and Life Sciences
Professor Allsop’s research and postgraduate teaching focuses on neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-Jakob Disease, Huntington’s disease, motor neuron disease, and other related disorders.
“My research is concerned with the mechanism of formation and deposition of protein aggregates in these various diseases, and on the potential relationship between protein aggregation, neu- rodegeneration and cell loss. I am very interested in novel approaches to improved diagnosis and therapy of these diseases, and have been able to establish links with industrial collaborators in these areas.“
“In the Biomedical and Life Sciences Division we are responsible for the co-ordination of biomedical research activities and strategy at Lancaster University and research into a diverse range of topics such as cancer biology, neurode- generative disease, microbiology, cell biology and biochemistry and reproductive immunology. This year we look forward to making further improvements to our excellent biomedical research facilities and laboratories.”
Research carried out by the Biomedical and Life Sciences Division is world class and ranked in the top 5% of its discipline in the 2008 RAE. It benefits greatly from links with many NHS trusts and receives financial support from The Alzheimer’s Disease Society, Arthritis Research Campaign, BBSRC, MRC, The Colt Foundation, DEFRA, DoH, EPSRC, International Association for Cancer Research, Leukaemia Research Fund, North West Cancer Research Fund, Parkinson’s Disease Society, Pfizer, TFC Frost Trust, Research into Ageing, Royal Institute for Prevention of Blindness, The Royal Society, The EU, and The Wellcome Trust. Total grant funding over the past 5 years has exceeded £5M.
Research includes neurodegenerative disorders, carcinogenesis, leukaemogenesis, eye disease, biochemical toxicology, immunology, microbiology and molecular parasitology as well as fundamental cellular and physiological processes underlying human disease.
TAUGHT COURSES MSc in Biomedicine
Director of Studies: Dr Nigel Fullwood. Duration: 12 months full-time, 24 months part-time. Entry Requirements: At least a second class honours degree, or its equivalent, in an appropriate subject. Assessment: Combination of coursework, presentations, examinations and dissertation. IELTS: 6.5 Funding: Please see page 213. Further Information:
www.lancs.ac.uk/shm/bls/
The MSc in Biomedicine at Lancaster provides the opportunity for you to acquire a greater understanding of practical and theoretical biomedical science in the leading university in this field of research. The course is intended to provide the knowledge and skills for subsequent progression to PhD study, a career in biomedical/pharmaceutical research (industry or university based) or hospital-based employment. Our scheme is designed to provide focus and training within several ‘hot’ topics in biomedicine whilst still retaining elements of flexibility and choice.
104 School of Health and Medicine
Profile
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220 |
Page 221 |
Page 222 |
Page 223 |
Page 224 |
Page 225 |
Page 226 |
Page 227 |
Page 228